CL2018000015A1 - Moléculas de fusión - Google Patents

Moléculas de fusión

Info

Publication number
CL2018000015A1
CL2018000015A1 CL2018000015A CL2018000015A CL2018000015A1 CL 2018000015 A1 CL2018000015 A1 CL 2018000015A1 CL 2018000015 A CL2018000015 A CL 2018000015A CL 2018000015 A CL2018000015 A CL 2018000015A CL 2018000015 A1 CL2018000015 A1 CL 2018000015A1
Authority
CL
Chile
Prior art keywords
fusion molecules
aeruginosa
molecules
trencience
piokeline
Prior art date
Application number
CL2018000015A
Other languages
English (en)
Inventor
Carsten Corvey
Heike Stump
Jochen Kruip
Christian Lange
Ingo Focken
Dorothea Rat
Thomas Stuedemann
Hans-Falk Rasser
Juergen Schaefer
Bernhard Calandra
Astrid Rey
Michael Mourez
Laurent Fraisse
Christine Rothe
Andrea Allersdorfer
Alexander Wiedenmann
Marlon Hinner
Bradley Lunde
Kristian Jensen
Martin Hülsmeyer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2018000015A1 publication Critical patent/CL2018000015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)

Abstract

<p>MOLÉCULAS DE FUSIÓN CON ESPECIFICIDAD DE UNIÓN PARA PIOVERDINA TIPO I, II Y III Y PIOQUELINA EN APLICACIONES DE DIAGNÓSTICO Y/O TERAPÉUTICAS, TAL COMO INHIBIR O REDUCIR CRECIMIENTO DE P. AERUGINOSA Y/O PREVENIR O TRATAR INFECCIÓN Y ENFERMEDADES O TRASTORNOS ASOCIADOS CON INFECCIÓN POR BIOPELÍCULA DE P. AERUGINOSA. MÉTODOS PARA PRODUCIR LAS MOLÉCULAS DE FUSIÓN ASÍ COMO A COMPOSICIONES Y KITS. MOLÉCULAS DE ÁCIDO NUCLEICO QUE CODIFICAN DICHAS MOLÉCULAS DE FUSIÓN.</p>
CL2018000015A 2015-07-07 2018-01-03 Moléculas de fusión CL2018000015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306106.4A EP3115371A1 (en) 2015-07-07 2015-07-07 Fusion molecules

Publications (1)

Publication Number Publication Date
CL2018000015A1 true CL2018000015A1 (es) 2018-07-13

Family

ID=53719726

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000015A CL2018000015A1 (es) 2015-07-07 2018-01-03 Moléculas de fusión

Country Status (26)

Country Link
US (2) US10316071B2 (es)
EP (2) EP3115371A1 (es)
JP (1) JP2018524003A (es)
KR (1) KR20180026755A (es)
CN (1) CN107849106A (es)
AR (1) AR105257A1 (es)
AU (1) AU2016289839A1 (es)
BR (1) BR112018000155A2 (es)
CA (1) CA2991298A1 (es)
CL (1) CL2018000015A1 (es)
CO (1) CO2018001188A2 (es)
CR (1) CR20180079A (es)
DO (1) DOP2018000001A (es)
EA (1) EA201890234A1 (es)
EC (1) ECSP18008488A (es)
HK (1) HK1249110A1 (es)
IL (1) IL256694A (es)
MA (1) MA42006A1 (es)
MX (1) MX2018000206A (es)
PE (1) PE20180490A1 (es)
PH (1) PH12018500058A1 (es)
TN (1) TN2017000547A1 (es)
TW (1) TW201716435A (es)
UY (1) UY36772A (es)
WO (1) WO2017005763A1 (es)
ZA (1) ZA201708754B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
US20220168387A1 (en) * 2019-03-29 2022-06-02 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CN1170543C (zh) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7056702B2 (en) 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP3381933B1 (en) * 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US10526384B2 (en) * 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
CN107849106A (zh) 2018-03-27
ZA201708754B (en) 2018-11-28
AU2016289839A1 (en) 2018-03-01
WO2017005763A1 (en) 2017-01-12
BR112018000155A2 (pt) 2018-09-11
MX2018000206A (es) 2018-02-26
UY36772A (es) 2017-01-31
US20190382455A1 (en) 2019-12-19
CO2018001188A2 (es) 2018-05-10
HK1249110A1 (zh) 2018-10-26
US10947284B2 (en) 2021-03-16
AR105257A1 (es) 2017-09-20
PH12018500058A1 (en) 2018-07-09
PE20180490A1 (es) 2018-03-07
TW201716435A (zh) 2017-05-16
US20170029477A1 (en) 2017-02-02
EP3319986A1 (en) 2018-05-16
JP2018524003A (ja) 2018-08-30
CA2991298A1 (en) 2017-01-12
TN2017000547A1 (en) 2019-04-12
IL256694A (en) 2018-03-29
US10316071B2 (en) 2019-06-11
KR20180026755A (ko) 2018-03-13
EA201890234A1 (ru) 2018-06-29
EP3115371A1 (en) 2017-01-11
MA42006A1 (fr) 2018-09-28
ECSP18008488A (es) 2018-04-30
DOP2018000001A (es) 2018-05-15
CR20180079A (es) 2018-04-24

Similar Documents

Publication Publication Date Title
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2016002571A (es) Regulador de ph de transduccion.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
EA039598B9 (ru) Соединение, нацеленное на ил-23а и фно-альфа, и его применение
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
MX2017010746A (es) Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas.
MX385926B (es) Proteínas de fusión de citoquinas.
MY188541A (en) Besifloxacin for the treatment of resistant acne
CO2017001884A2 (es) Polimorfos de selinexor
MX385048B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
MX2016010105A (es) Derivados de nucleosido sustituidos con 4´ -difluorometilo como inhibidores de la replicacion de arn de la infuenza.
CL2017001113A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
UY37017A (es) Inhibidores aza-bencimidazol de pad4
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
PH12016500574A1 (en) Compositions and methods for inhibiting expression of the alas1 gene
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
BR112017008481A2 (pt) composto antimicótico
MX2016013308A (es) Uso de oxotetrahidroquinolinilsulfonamidas sustituidas o sus sales para aumentar la tolerancia al estres en plantas.
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas